These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Author: Falsetti L, Galbignani E.
    Journal: Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631.
    Abstract:
    This study evaluates the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome (PCOS). During the administration of the pill a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase of the Sex Hormone Binding Globulin (SHBG). The progressive decrease of the total androgenic activity explains the clinical results that have been obtained: at the 36th cycle of therapy acne disappeared in 100% of the cases, seborrea in 76.4% and hirsutism in 75%. Our results underline the need for a continuous administration without interruption of the pill with CPA in patients with clinical hyperandrogenic symptoms. This study evaluated the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg ethinyl estradiol and 2 mg cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome. During the administration of the pill, a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase in sex hormone binding globulin. The progressive decrease in total androgenic activity explains the clinical results that have been obtained--at the 36th cycle of therapy, acne disappeared in 100% of the cases, seborrhea in 76.4%, and hirsutism in 75%. These results underline the need for continuous administration of the pill with CPA without interruption in patients with clinical hyperandrogenic symptoms.
    [Abstract] [Full Text] [Related] [New Search]